Detall de la convocatòria


Objectiu de la convocatòria
Grants for basic science or translational research relevant to the understanding of the pathophysiology and treatment of haemostatic disorders.
Característiques principals
The research priorities are the interactions of blood coagulation components (cells and proteins) and treatment of haemophilia. Topics could include the following:
  • In vitro and in vivo models to evaluate therapeutics for haemophilia and rare bleeding disorders
  • Better understanding of mode of action of novel agents for treating haemophilia
  • Insights into the use of gene therapy for treating haemophilia
  • Investigations into phenotypic variations in haemophilia clinical severity
  • Molecular basis for inhibitor development and optimal tolerization in patients with haemophilia
  • Mechanism of action of bypassing agents in the treatment of inhibitor patients
  • The function and regulation of platelets in haemostatic disorders
  • Platelet receptors and clotting factor interactions in haemostatic disorders
  • Cell trafficking and bio-distribution of clotting factors
  • Diagnosis and treatment of von Willebrand disease and platelet disorders
    In order to maintain a focus on interactions of blood coagulation components and haemophilia treatment, Access to Insight basic research grants will not support research focused on:
  • Products or technologies licensed or patented by competitors of Novo Nordisk
  • Pathophysiology, diagnosis, and treatment of blood transmitted diseases Thrombotic disorders
  • Lloc de presentació
    IMIM and PSMAR staff who need more information should contact::
    Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.04.00.
    Carol Barnwell: Ext.: 1670
    Marta López: Ext.: 1576
    Convocatòria (URL)
    €70,000 that can be used to cover salary and/or project costs.
    12–18 month period.


    Novo Nordisk - Your Access to Insight - Supporting global haemostasis research.pdf